



09-18-01

CAN 1635

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 99,569-A)

In the Application of:

Nakayama et al.

Serial No.: 09/724,915

Filing Date: November 28, 2000

For: Chordin-Like Molecules and Uses  
Thereof

Examiner: To be Assigned

Group Art Unit: 1635

TRANSMITTAL LETTER

Express Mail Number **EL921553857US**  
Commissioner for Patents  
Washington, D.C. 20231

TECH CENTER 1600/2900

SEP 19 2001


RECEIVED

Dear Sir:

- In regard to the above identified application,
1. We are transmitting herewith the attached:
    - a) Supplemental Information Disclosure Statement;
    - b) PTO Form 1449; and cited references
    - c) Return postcard
  2. With respect to fees:
    - a) No fees are required
    - b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.
  3. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1, are being deposited with the United States Postal Service Express Mail to the Commissioner for Patents, Washington, D.C. 20231 on September 17, 2001.

Respectfully submitted,

Date: 17 September 2001

  
Donald L. Zuhn, Jr.  
Registration No. P48,710



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 99,569-A)

#6  
29  
9/20/01  
RECEIVED  
SEP 19 2001  
TECH CENTER 1600/2900

In the Application of:

Nakayama et al.

Serial No.: 09/724,915

Filing Date: November 28, 2000

For: Chordin-Like Molecules and Uses  
Thereof

Examiner: To be Assigned

Group Art Unit: 1635

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**


Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references cited below are enclosed. These references are also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned representative by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.



**FOREIGN PATENTS**

WO 99/67192 A	Genetics Inst.	11 November 1999
WO 98/40483	Human Genome Sciences Inc.	17 September 1998
WO 99/31236	Bougueleret Lydie; Genset SA	24 June 1999
WO 00/09551	Genetics Inst. 24	24 February 2000

TECH CENTER 1600/2900

SEP 19 2001

RECEIVED

**OTHER DOCUMENTS**

Database EMBL 'Online' Pearce, A. Human DNA sequence from clone 141HS on chromosome Xq22. 1-23. Contains parts of a novel Chordin Like protein with Von Willebrand factor type C domains. Contains ESTs, STSs and GSSs."


Database EMBL 'Online' Coffinie, C.C. et al. "Mus musculus neuralin mRNA, complete cds"

Nakayama Naoki et al. "A Novel chordin-like protein inhibitor for bone morphogenetic proteins expressed preferentially in mesenchymal cell lineages." Developmental Biology vol. 232, no. 2, 4-15-01 pgs. 372-387

Date: September 17, 2001

Respectfully submitted,

**McDonnell Boehnen Hulbert & Berghoff**



Donald L. Zuhn

Reg. No. P48,710